Critically and Moderately Ill COVID-19 Patients Have Different Risk Factors for Arterial Thromboembolism and Risk Score for Critically Ill Patientsстатья
Аннотация:Background. COVID-19 infection can lead to thromboembolic events, including arterial thromboembolism (ATE). The frequency of these events increases in critically ill patients due to yet not clearly established additional risk factors. Objectives. We aimed to identify risk factors for ATE in moderately and critically ill COVID-19 patients and develop a risk scale for the latter. Methods. We conducted a prospective multicenter study enrolling 3,850 patients with critical and moderate COVID-19 infection. These groups were predetermined by admission to the intensive care unit (ICU) or non-ICU respectively. Results. ATE developed in 32 ICU patients (3.34%) and 32 non-ICU patients (1.12%). The risk factors for ATE in critical cases included elevated neutrophil count, atrial fibrillation (AF), chronic kidney disease (CKD), and male sex. In moderate cases, the risk factors were atherosclerosis, CKD, and male sex. A prognostic scale for ATE in critically ill COVID-19 was developed and showed high predictive value (AUC 0.767, 95% CI: 0.739-0.793). Conclusion. The risk factors for ATE differed in critical and moderate cases of COVID-19. Common factors were CKD and male sex, while neutrophilia was an ATE predictor in severe cases. We propose our prognostic scale for risk stratification.Keywords: Acute Ischemic Stroke, COVID-19, Critical Illness, Myocardial Infarction, ThromboembolismDeclaration of InterestThe authors declare no conflicts of interest.Ethics ApprovalThe study was conducted in accordance with the declaration of Helsinki. Written in-formed consent was obtained from all patients before any study-related procedures. The study protocol was approved by the Independent Ethical Committee of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Healthcare of Russia, Moscow.Funder StatementThis study was supported by the Russian Science Foundation (grant No. 22-15-00164).Clinical Trial RegistrationThe study was carried out as part of the Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers Clinical Trial (CoViTro-I; ClinicalTri-als.gov NCT05330832).